Hepatoprotective Mechanism of Ginsenoside Rg1 against Alcoholic Liver Damage Based on Gut Microbiota and Network Pharmacology

Oxid Med Cell Longev. 2022 Aug 23:2022:5025237. doi: 10.1155/2022/5025237. eCollection 2022.

Abstract

Alcoholic liver disease (ALD) is a major public health problem worldwide, which needs to be effective prevention. Ginsenoside Rg1 (GRg1), a bioactive ingredient extracted from ginseng, has benefit effects on health. In this study, 11 potential targets of GRg1 against ALD were firstly obtained by network pharmacology. KEGG pathway enrichment showed that GRg1-target-ALD was closely related to Toll-like receptor (TLR) and nuclear factor-kappa B (NF-κB) signaling pathways. In addition, GRg1 decreased antioxidant levels and increased oxidative levels in alcohol-treated mice, which alleviated oxidative stress-induced hepatic damage. GRg1 enhanced intestinal barrier function via upregulating the levels of tight junction protein and immunoglobulin A. GRg1 also reduced alcohol-induced inflammation by suppressing TLR4/NF-κB pathway, which was consistent with the prediction of network targets. Moreover, GRg1 altered GM population, and Verrucomicrobia, Bacteroidetes, Akkermansia, Bacteroides, Lachnospiraceae_NK4A136_group, and Alloprevotella played positive association with intestinal barrier indicators and negative correlation with hepatic inflammation biomarkers. The results suggest that GRg1 administration might be a promising strategy for protection of alcohol-induced liver damage.

MeSH terms

  • Animals
  • Ethanol / adverse effects
  • Gastrointestinal Microbiome*
  • Ginsenosides
  • Inflammation / metabolism
  • Liver / metabolism
  • Liver Diseases, Alcoholic* / drug therapy
  • Liver Diseases, Alcoholic* / metabolism
  • Mice
  • NF-kappa B / metabolism
  • Network Pharmacology

Substances

  • Ginsenosides
  • NF-kappa B
  • Ethanol
  • ginsenoside Rg1